ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 622,02
1,16%
Dow Jones
40 415,44
0,32%
DAX
18 407,07
1,33%
Brent Oil
81,64
0,15%
Bitcoin
67 316,82
-0,43%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. XTL Biopharmaceuticals Ltd (XTLB)

  7. XTL Biopharmaceuticals Ltd (XTLB) Actualités

XTLB

XTL Biopharmaceuticals (XTLB)

XTL Biopharmaceuticals Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:XTLB
DateHeureSourceTitreSymboleSociété
22/07/202422h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/06/202415h15GlobeNewswire Inc.XTL Entered Definitive Agreement to Acquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/03/202415h15GlobeNewswire Inc.XTL To Aquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00GlobeNewswire Inc.XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00GlobeNewswire Inc.XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelNASDAQ:XTLBXTL Biopharmaceuticals Ltd
16/05/202317h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
01/02/202315h53Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
30/03/202223h16Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
08/06/202112h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/05/202117h31Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/08/202015h24Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
13/01/202012h39Edgar (US Regulatory)Amended Report of Foreign Issuer (6-k/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
01/11/201815h09PR Newswire (US)XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/07/201815h09PR Newswire (US)XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
29/05/201823h37PR Newswire (US)XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
07/03/201822h05Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
28/02/201822h04Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/01/201821h51Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
06/12/201718h08PR Newswire (US)XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing RequirementsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
27/11/201716h30PR Newswire (US)XTL Biopharmaceuticals Reports Third Quarter 2017 Financial ResultsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
23/10/201717h23PR Newswire (US)XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing RequirementsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
26/09/201715h23PR Newswire (US)XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
12/09/201716h24PR Newswire (US)XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's SyndromeNASDAQ:XTLBXTL Biopharmaceuticals Ltd
15/06/201715h38PR Newswire (US)XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
27/04/201715h50PR Newswire (US)XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of DirectorsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/04/201715h10PR Newswire (US)XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s SyndromeNASDAQ:XTLBXTL Biopharmaceuticals Ltd
30/03/201714h55PR Newswire (US)XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
29/03/201723h01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
22/03/201714h22PR Newswire (US)XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing InvestorsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
07/03/201718h40PR Newswire (US)XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing InvestorsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:XTLB

Dernières Valeurs Consultées

NASDAQ
GIIX
Gores Holdings VIII
NYSE
DDS
Dillards
NASDAQI
DWAMLPN
DWA MLP Select Net Total...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés